All In Biotech

Drug Trial Radar · NCT07594314

Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)

Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 860 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

860

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Xiang LuoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are closely associated with post-recanalization neuroinflammation. Minocycline is a second-generation tetracycline with pleiotropic neuroprotective effects, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Prior preclinical and clinical studies suggest that minocycline may improve neurological outcomes in acute ischemic stroke. This study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute anterior circulation LVO who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces futile recanalization.

Conditions

  • Acute Ischemic Stroke
  • Vessel Occlusion
  • Endovascular Thrombectomy
  • Anterior Circulation Brain Infarction
  • Minocycline

Interventions

  • Minocycline hydrochloride capsuleDrug

    50 mg per capsule, containing 50mg of Minocycline Hydrochloride.

  • Placebo capsules of Minocycline hydrochloride capsulesDrug

    50 mg per capsule, containing 0mg of Minocycline Hydrochloride.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Excellent outcomeTime frame: 90±7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.